Although KRAS G12C specific inhibitors have been approved but there are a large number of patients harboring mutations with KRAS G12D, G12V cancers are still undruggable. Despite the approval of KRAS G12C inhibitors, there remains a large patient population that may benefit from inhibition of other RAS mutations, particularly KRAS G12D and KRAS G12V which are highly prevalent in cancers of the colon, pancreas and lung.